Research programme: cannabinoid receptor modulators - CeNeRx BioPharma

Drug Profile

Research programme: cannabinoid receptor modulators - CeNeRx BioPharma

Alternative Names: CXB 006; CXB 029; CXB 040; CXB070; NESS 006A; NESS040C5; NESS070C5

Latest Information Update: 28 Jun 2013

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator PharmaNess Neuroscience
  • Developer CeNeRx BioPharma
  • Class Cannabinoids
  • Mechanism of Action Cannabinoid receptor CB1 agonists; Cannabinoid receptor CB1 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Glaucoma; Muscle spasticity; Obesity; Pain

Most Recent Events

  • 28 Jun 2013 Discontinued - Preclinical for Glaucoma in USA (unspecified route)
  • 28 Jun 2013 Discontinued - Preclinical for Obesity in USA (unspecified route)
  • 28 Jun 2013 Discontinued - Preclinical for Pain in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top